Published on
Earlier in October, Professor Erika Lietzan spoke at the University of Burgundy in Dijon, France at a conference on the Regulation of Innovative Medical Therapies. She presented an overview of U.S. regulation of cellular therapies, engineered tissue products, and gene therapy, and talked about how U.S. regulation differs from EU regulation of these products.
The next day, Professor Lietzan spoke on the same topic at a much larger conference, known as Innovative Therapies Days, which took place in Besancon, France. Professor Lietzan writes extensively about U.S. regulation of biological products, and has published before on how U.S. and EU law differ with respect to regulation of medical therapies.